EUVIMEDEUVIMED entdecken
Crossref

In Brief: Furoscix - A Subcutaneous Furosemide Infusor for Heart Failure

The Medical Letter on Drugs and Therapeutics · 2023

DOI: 10.58347/tml.2023.1668d ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2023. Hauptthemen laut MEDLINE: Furosemide, Heart Failure. Die Arbeit wurde bisher 2-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The FDA has approved Furoscix (scPharmaceuticals), a subcutaneous formulation of the loop diuretic furosemide administered via a single-use, on-body infusor, for treatment of congestion due to fluid overload in adults with New York Heart Association (NYHA) Class II-III chronic heart failure (HF). Furosemide (Lasix, and generics) has been available for years in oral and IV formulations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FurosemideHeart FailureHumansSulfonamides

Stichwörter der Autor:innen

FuroscixLasixadverse effectsbumetanidediureticsdosageefficacyfurosemideheart failuresafetytorsemide

Substanzen

FurosemideSulfonamides

Zitieren

APA

(2023). In Brief: Furoscix - A Subcutaneous Furosemide Infusor for Heart Failure. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2023.1668d

Vancouver

In Brief: Furoscix - A Subcutaneous Furosemide Infusor for Heart Failure. The Medical Letter on Drugs and Therapeutics. 2023. doi:10.58347/tml.2023.1668d

BibTeX
@article{euvimed2023,
  title = {In Brief: Furoscix - A Subcutaneous Furosemide Infusor for Heart Failure},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2023},
  doi = {10.58347/tml.2023.1668d}
}
Kostenlos starten →